4
9.67
0.77 (8.65%)
| Previous Close | 8.90 |
| Open | 8.87 |
| Volume | 1,877,169 |
| Avg. Volume (3M) | 1,221,543 |
| Market Cap | 451,612,864 |
| Price / Sales | 14.64 |
| Price / Book | 0.960 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Operating Margin (TTM) | -383,007.15% |
| Diluted EPS (TTM) | -3.18 |
| Quarterly Revenue Growth (YOY) | -50.00% |
| Total Debt/Equity (MRQ) | 5.08% |
| Current Ratio (MRQ) | 12.36 |
| Operating Cash Flow (TTM) | -153.26 M |
| Levered Free Cash Flow (TTM) | -90.21 M |
| Return on Assets (TTM) | -22.18% |
| Return on Equity (TTM) | -32.97% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | 4D Molecular Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
-0.9
| Analyst Consensus | 1.0 |
| Insider Activity | -1.5 |
| Price Volatility | -4.5 |
| Technical Moving Averages | -3.5 |
| Technical Oscillators | 4.0 |
| Average | -0.90 |
|
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.88% |
| % Held by Institutions | 95.91% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 38.00 (Roth Capital, 292.97%) | Buy |
| Median | 26.00 (168.87%) | |
| Low | 25.00 (Chardan Capital, 158.53%) | Buy |
| Average | 29.67 (206.83%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 7.85 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 21 Oct 2025 | 26.00 (168.87%) | Buy | 11.24 |
| Chardan Capital | 12 Aug 2025 | 25.00 (158.53%) | Buy | 6.15 |
| Roth Capital | 12 Aug 2025 | 38.00 (292.97%) | Buy | 6.15 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 30 Oct 2025 | Announcement | 4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific |
| 17 Oct 2025 | Announcement | 4DMT Announces New Employment Inducement Grants |
| 14 Oct 2025 | Announcement | 4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference |
| 13 Oct 2025 | Announcement | 4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation |
| 12 Sep 2025 | Announcement | 4DMT Announces New Employment Inducement Grants |
| 02 Sep 2025 | Announcement | 4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness |
| 25 Aug 2025 | Announcement | 4DMT to Participate in Upcoming Investor Conferences |
| 15 Aug 2025 | Announcement | 4DMT Announces New Employment Inducement Grants |
| 11 Aug 2025 | Announcement | 4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |